Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Overcoming lack of diversity in cancer clinical trials

Ruben Mesa • 8 Jun 2020
EHA 2020
General

Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, highlights the importance of overcoming the lack of diversity in patients enrolled in clinical trials. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ruben Mesa

Insights into the evolving treatment landscape for MPNs: current state and future directions
2:22
Insights into the evolving treatment landscape for MPNs: current state and future directions
Ruben Mesa • 12 Jun 2026
Targeting hepcidin in polycythemia vera and myelofibrosis
1:58
Targeting hepcidin in polycythemia vera and myelofibrosis
Ruben Mesa • 12 Jun 2026
Early versus delayed initiation of ropeginterferon alfa-2b in high-risk ET in the SURPASS-ET trial
2:28
Early versus delayed initiation of ropeginterferon alfa-2b in high-risk ET in the SURPASS-ET trial
Ruben Mesa • 12 Jun 2026
Reflecting on the progress made in the treatment of MPNs over the past 20 years
1:04
Reflecting on the progress made in the treatment of MPNs over the past 20 years
Ruben Mesa • 6 Dec 2025

Related Videos

From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
2:58
From immunosuppression to targeted immunomodulation: emerging treatment strategies in GvHD
Iskra Pusic • 11 Sep 2026
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
3:46
Three-year survival update of pre-induction azacitidine and venetoclax in newly diagnosed AML
Maher Salamoon • 8 Sep 2026
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
2:01
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
Michael Jain • 11 Sep 2026
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
1:46
Long-term survivorship after CAR T-cell therapy: addressing non-relapse mortality
Michael Jain • 11 Sep 2026
The content of VJHemOnc is intended for healthcare professionals